September 30, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) announced on September 26 that Astellas Pharma’s anticancer drug enzalutamide (brand name: Xtandi) is being evaluated for the risk of thrombocytopenia. Certain safety measures such as the revision of the precautions section of...read more